$VNDA
Vanda Pharmaceuticals Inc.

2018 Q2 Form 10-Q Financial Statement

#000134717818000007 Filed on August 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $47.35M $42.06M
YoY Change 12.59% 16.73%
Cost Of Revenue $5.213M $4.529M
YoY Change 15.1% -30.26%
Gross Profit $41.74M $37.10M
YoY Change 12.52% 39.49%
Gross Profit Margin 88.15% 88.2%
Selling, General & Admin $27.96M $31.37M
YoY Change -10.87% 27.1%
% of Gross Profit 66.99% 84.57%
Research & Development $9.866M $7.648M
YoY Change 29.0% 14.15%
% of Gross Profit 23.64% 20.62%
Depreciation & Amortization $800.0K $700.0K
YoY Change 14.29% -78.13%
% of Gross Profit 1.92% 1.89%
Operating Expenses $37.83M $39.02M
YoY Change -3.06% 24.34%
Operating Profit $3.913M -$1.924M
YoY Change -303.38% -59.82%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $790.0K $400.0K
YoY Change 97.5% 135.29%
Pretax Income $4.701M -$1.527M
YoY Change -407.86% -66.93%
Income Tax $90.00K $7.000K
% Of Pretax Income 1.91%
Net Earnings $4.611M -$1.534M
YoY Change -400.59% -66.78%
Net Earnings / Revenue 9.74% -3.65%
Basic Earnings Per Share $0.09 -$0.03
Diluted Earnings Per Share $0.09 -$0.03
COMMON SHARES
Basic Shares Outstanding 52.17M shares 44.72M shares
Diluted Shares Outstanding 53.95M shares 44.72M shares

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $231.2M $137.1M
YoY Change 68.63% 0.83%
Cash & Equivalents $60.89M $14.23M
Short-Term Investments $170.3M $122.9M
Other Short-Term Assets $11.80M $3.001M
YoY Change 293.2% -68.07%
Inventory $1.193M $742.0K
Prepaid Expenses
Receivables $24.86M $21.02M
Other Receivables $0.00 $0.00
Total Short-Term Assets $269.1M $174.6M
YoY Change 54.12% 8.87%
LONG-TERM ASSETS
Property, Plant & Equipment $4.800M $5.709M
YoY Change -15.92% 34.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.700M $3.400M
YoY Change 8.82% -24.44%
Total Long-Term Assets $33.82M $36.06M
YoY Change -6.21% -13.44%
TOTAL ASSETS
Total Short-Term Assets $269.1M $174.6M
Total Long-Term Assets $33.82M $36.06M
Total Assets $302.9M $210.7M
YoY Change 43.79% 4.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.700M $3.600M
YoY Change 30.56% -40.0%
Accrued Expenses $40.20M $46.90M
YoY Change -14.29% 2.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.88M $75.44M
YoY Change -37.85% 45.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.774M $3.817M
YoY Change 25.07% 4.2%
Total Long-Term Liabilities $4.774M $3.817M
YoY Change 25.07% 4.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.88M $75.44M
Total Long-Term Liabilities $4.774M $3.817M
Total Liabilities $51.66M $79.25M
YoY Change -34.82% -1.46%
SHAREHOLDERS EQUITY
Retained Earnings -$353.7M -$355.0M
YoY Change -0.36% 2.96%
Common Stock $604.9M $486.4M
YoY Change 24.36% 4.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $251.3M $131.4M
YoY Change
Total Liabilities & Shareholders Equity $302.9M $210.7M
YoY Change 43.79% 4.27%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income $4.611M -$1.534M
YoY Change -400.59% -66.78%
Depreciation, Depletion And Amortization $800.0K $700.0K
YoY Change 14.29% -78.13%
Cash From Operating Activities $4.400M -$2.200M
YoY Change -300.0% -33.33%
INVESTING ACTIVITIES
Capital Expenditures -$25.10M -$600.0K
YoY Change 4083.33% 500.0%
Acquisitions
YoY Change
Other Investing Activities -$76.10M -$5.200M
YoY Change 1363.46% -60.61%
Cash From Investing Activities -$101.3M -$5.800M
YoY Change 1646.55% -56.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.500M 2.200M
YoY Change 13.64% 120.0%
NET CHANGE
Cash From Operating Activities 4.400M -2.200M
Cash From Investing Activities -101.3M -5.800M
Cash From Financing Activities 2.500M 2.200M
Net Change In Cash -94.40M -5.800M
YoY Change 1527.59% -62.82%
FREE CASH FLOW
Cash From Operating Activities $4.400M -$2.200M
Capital Expenditures -$25.10M -$600.0K
Free Cash Flow $29.50M -$1.600M
YoY Change -1943.75% -50.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001347178
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52379445 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
us-gaap Other Income
OtherIncome
1410000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-210000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-113000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5872000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0266
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.40
dei Entity Registrant Name
EntityRegistrantName
Vanda Pharmaceuticals Inc.
dei Trading Symbol
TradingSymbol
VNDA
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20335000 USD
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18562000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17601000 USD
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24855000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3961000 USD
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2793000 USD
CY2017Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4394000 USD
CY2018Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4684000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-63000 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
63000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
29000 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
16000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-34000 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
79000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
492802000 USD
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
604889000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5872000 USD
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2656000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4912000 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2721000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5872000 USD
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
432000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
886000 USD
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
398000 USD
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
800000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
750000 USD
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3409711 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3285106 shares
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1364535 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1210990 shares
CY2017Q4 us-gaap Assets
Assets
205425000 USD
CY2018Q2 us-gaap Assets
Assets
302926000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
169857000 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
269102000 USD
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
113782000 USD
CY2018Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
203300000 USD
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
109786000 USD
CY2018Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
170325000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33627000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60891000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41256000 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15065000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34335000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61635000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26191000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27300000 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44938133 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52375945 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44938133 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52375945 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
45000 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1573000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9226000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4718000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7790000 USD
CY2018Q2 us-gaap Contractual Obligation
ContractualObligation
37004000 USD
CY2018Q2 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
13089000 USD
CY2018Q2 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
2811000 USD
CY2018Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
3227000 USD
CY2018Q2 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
8866000 USD
CY2018Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
3352000 USD
CY2018Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
5659000 USD
CY2017Q2 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
4529000 USD
us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
8532000 USD
CY2018Q2 us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
5213000 USD
us-gaap Cost Of Goods Sold Excluding Depreciation Depletion And Amortization
CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization
9773000 USD
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
43980000 USD
us-gaap Costs And Expenses
CostsAndExpenses
89301000 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
43437000 USD
us-gaap Costs And Expenses
CostsAndExpenses
84587000 USD
us-gaap Depreciation
Depreciation
553000 USD
us-gaap Depreciation
Depreciation
706000 USD
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5323000 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5035000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
34872000 USD
CY2018Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
35622000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
60941000 USD
CY2018Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
60941000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26069000 USD
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
25319000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1527000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9153000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
4701000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
7765000 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
90000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
88000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2646000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1568000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
756000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7294000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
71000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3921000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3743000 USD
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
760000 USD
CY2018Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1127000 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
840000 USD
CY2018Q2 us-gaap Inventory Net
InventoryNet
1193000 USD
CY2017Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
3316000 USD
CY2018Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
2897000 USD
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
80000 USD
CY2018Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
66000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
147000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
672000 USD
CY2017Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
800000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1600000 USD
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1800000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
74038000 USD
CY2018Q2 us-gaap Liabilities
Liabilities
51655000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
205425000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
302926000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70363000 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
46881000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4402000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
106222000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-22996000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-84951000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7617000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
6029000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1534000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9179000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
4611000 USD
us-gaap Net Income Loss
NetIncomeLoss
7677000 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
300000 USD
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1924000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9830000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3913000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
6355000 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
23979000 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2355000 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2337000 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2505000 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2495000 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
13089000 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1198000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1994000 USD
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1921000 USD
CY2018Q2 us-gaap Other Commitment
OtherCommitment
2000000 USD
CY2018Q2 us-gaap Other Commitment Due After Fifth Year
OtherCommitmentDueAfterFifthYear
0 USD
CY2018Q2 us-gaap Other Commitment Due In Fifth Year
OtherCommitmentDueInFifthYear
0 USD
CY2018Q2 us-gaap Other Commitment Due In Fourth Year
OtherCommitmentDueInFourthYear
0 USD
CY2018Q2 us-gaap Other Commitment Due In Second Year
OtherCommitmentDueInSecondYear
0 USD
CY2018Q2 us-gaap Other Commitment Due In Third Year
OtherCommitmentDueInThirdYear
0 USD
CY2018Q2 us-gaap Other Commitments Future Minimum Payments Remainder Of Fiscal Year
OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear
2000000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-56000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-68000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
132000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
126000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
17000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
21000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-25000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-13000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-39000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
107000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
113000 USD
CY2017Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 USD
CY2017Q2 us-gaap Other Income
OtherIncome
397000 USD
us-gaap Other Income
OtherIncome
677000 USD
CY2018Q2 us-gaap Other Income
OtherIncome
788000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3675000 USD
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4774000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
81171000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
130536000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1102000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
210000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8003000 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11838000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100870000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
59277000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
70795000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4402000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5352000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5306000 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4800000 USD
CY2018Q2 us-gaap Purchase Obligation
PurchaseObligation
11025000 USD
CY2018Q2 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0 USD
CY2018Q2 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
456000 USD
CY2018Q2 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
890000 USD
CY2018Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
6371000 USD
CY2018Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
847000 USD
CY2018Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
2461000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7648000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18215000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9866000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19282000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-361426000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-353749000 USD
CY2017Q2 us-gaap Revenues
Revenues
42056000 USD
us-gaap Revenues
Revenues
79471000 USD
CY2018Q2 us-gaap Revenues
Revenues
47350000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
61668000 USD
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27960000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54782000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4912000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
90942000 USD
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31371000 USD
us-gaap Revenues
Revenues
90942000 USD
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
42056000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
79471000 USD
CY2018Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
47350000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100870000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5352000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
131387000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
251271000 USD
CY2018Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1772658 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1830635 shares
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44718597 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44559368 shares
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53945640 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51101464 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44718597 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44559368 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52172982 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49270829 shares
CY2017Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
4663000 USD
CY2018Q2 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
4129000 USD
vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P60D
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
-2814000 USD
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
4259000 USD
CY2017Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
4193000 USD
CY2018Q2 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
3705000 USD
CY2017Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
408000 USD
CY2018Q2 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
388000 USD
CY2017Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
87000 USD
CY2018Q2 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
87000 USD
CY2017Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
2821000 USD
CY2018Q2 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
2422000 USD
CY2017Q4 vnda Milestone Obligation Under License Agreement Current
MilestoneObligationUnderLicenseAgreementCurrent
27000000 USD
CY2018Q2 vnda Milestone Obligation Under License Agreement Current
MilestoneObligationUnderLicenseAgreementCurrent
2000000 USD
vnda Option Awards Vesting Period After Completion Of One Year Of Service
OptionAwardsVestingPeriodAfterCompletionOfOneYearOfService
P3Y
CY2017 vnda Percentage At Which Certain Federal Deferred Tax Assets And Liabilities Remeasured
PercentageAtWhichCertainFederalDeferredTaxAssetsAndLiabilitiesRemeasured
0.21
vnda Percentage Of Future Sublicense Fees Payable
PercentageOfFutureSublicenseFeesPayable
mid-twenties
vnda Percentage Of Responsibility For Patients Cost Of Branded Prescription Under Medicare Part D
PercentageOfResponsibilityForPatientsCostOfBrandedPrescriptionUnderMedicarePartD
0.50
CY2017Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
23028000 USD
CY2018Q2 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
26319000 USD
vnda Share Based Compensation Arrangement By Share Based Payment Annual Award Vesting Period Directors
ShareBasedCompensationArrangementByShareBasedPaymentAnnualAwardVestingPeriodDirectors
P1Y
vnda Share Based Compensation Arrangement By Share Based Payment Award Initial Vesting Period Directors
ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialVestingPeriodDirectors
P4Y
vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#8217;s evaluation could change. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001347178-18-000007-index-headers.html Edgar Link pending
0001347178-18-000007-index.html Edgar Link pending
0001347178-18-000007.txt Edgar Link pending
0001347178-18-000007-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20180630.xml Edgar Link completed
vnda-20180630.xsd Edgar Link pending
vnda-20180630_cal.xml Edgar Link unprocessable
vnda-20180630_def.xml Edgar Link unprocessable
vnda-20180630_lab.xml Edgar Link unprocessable
vnda-20180630_pre.xml Edgar Link unprocessable
vnda0630201810q.htm Edgar Link pending
vndaex31106302018.htm Edgar Link pending
vndaex31206302018.htm Edgar Link pending
vndaex32106302018.htm Edgar Link pending